The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Penn and CHOP researchers want to develop urea cycle disorder treatments using CRISPR gene-editing therapy. Get unlimited access to Inquirer.com and The Inquirer App, plus 5 articles each month to ...

A U.S. biological research institute has developed a new genetic modification technique that promises a wide range of organism mutations while being safer than the ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...

From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.

Pioneering CRISPR trial shows single infusion permanently lowers bad cholesterol by 50% in patients who don't respond to medication.

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.